Key references: Pharmacological interventions for challenging behaviour in a person with developmental disability

  • Beumer S, Anne Maria Maes-Festen D. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: why does it fail? Lancet Psychiatry 2017;4(3):e2. https://www.ncbi.nlm.nih.gov/pubmed/28236957
  • Council of Australian Therapeutic Advisory Groups (CATAG). Rethinking medicines decision making in Australian Hospitals. Guiding principles for the quality use of off-label medicines. Darlinghurst: CATAG; 2013. https://www.catag.org.au/rethinking-medicines-decision-making/
  • Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review. Res Dev Disabil 2014;35(3):711–25. https://www.ncbi.nlm.nih.gov/pubmed/24405794
  • Deb S, Kwok H, Bertelli M, Salvador-Carulla L, Bradley E, Torr J, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 2009;8(3):181–6. https://www.ncbi.nlm.nih.gov/pubmed/19812757
  • Eady N, Courtenay K, Strydom A. Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability. Drugs Aging 2015;32(2):95–102. https://www.ncbi.nlm.nih.gov/pubmed/25573538
  • Flood B. De-prescribing of psychotropic medications in the adult population with intellectual disabilities: A commentary. Pharmacy (Basel) 2018;6(2). https://www.ncbi.nlm.nih.gov/pubmed/29601493
  • Gormez A, Rana F, Varghese S. Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities: Abridged republication of a Cochrane systematic review. J Psychopharmacol 2014;28(7):624–32. https://www.ncbi.nlm.nih.gov/pubmed/24785762
  • Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry 2016;29(2):103–25. https://www.ncbi.nlm.nih.gov/pubmed/26779860
  • Mahan S, Holloway J, Bamburg JW, Hess JA, Fodstad JC, Matson JL. An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil 2010;31(6):1561–9. https://www.ncbi.nlm.nih.gov/pubmed/20542660
  • McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry 2015;15:303. https://www.ncbi.nlm.nih.gov/pubmed/26611280
  • National Institute for Health and Care Excellence (NICE). Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges [NG11]. London: NICE; 2015. https://www.nice.org.uk/guidance/ng11
  • National Institute for Health and Care Excellence (NICE). Psychotropic medicines in people with learning disabilities whose behaviour challenges [KTT19]. London: NICE; 2019. https://www.nice.org.uk/advice/ktt19
  • O’Dwyer M, Peklar J, McCallion P, McCarron M, Henman MC. Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study. BMJ Open 2016;6(4):e010505. https://www.ncbi.nlm.nih.gov/pubmed/27044582
  • Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, et al. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. J Am Acad Child Adolesc Psychiatry 2016;55(6):456-68 e4. https://www.ncbi.nlm.nih.gov/pubmed/27238064
  • Practice Policy and Partnerships Committee (PPPC). Professional practice guideline 4: ‘off-label’ prescribing in psychiatry. Melbourne: The Royal Australian and New Zealand College of Psychiatrists; 2018. https://www.ranzcp.org/files/resources/college_statements/practice_guidelines/ppg-4-off-label-prescribing-in-psychiatry.aspx
  • Roughead L, Procter N, Westaway K, Sluggett J, Alderman C. Medication safety in mental health. Sydney: Australian Commission on Safety and Quality in Health Care (ACSQHC); 2017. https://www.safetyandquality.gov.au/sites/default/files/migrated/Medication-Safety-in-Mental-Health-final-report-2017.pdf
  • Scheifes A, Egberts TC, Stolker JJ, Nijman HL, Heerdink ER. Structured medication review to improve pharmacotherapy in people with intellectual disability and behavioural problems. J Appl Res Intellect Disabil 2016;29(4):346–55. https://www.ncbi.nlm.nih.gov/pubmed/25882186
  • Sheehan R, Hassiotis A. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry 2017;4(3):238–56. https://www.ncbi.nlm.nih.gov/pubmed/27838214
  • Sheehan R, Strydom A, Brown E, Marston L, Hassiotis A. Association of focused medication review with optimization of psychotropic drug prescribing: A systematic review and meta-analysis. JAMA Netw Open 2018;1(6):e183750. https://www.ncbi.nlm.nih.gov/pubmed/30646263
  • Trollor JN, Salomon C, Franklin C. Prescribing psychotropic drugs to adults with an intellectual disability. Aust Prescr 2016;39(4):126–30. https://www.ncbi.nlm.nih.gov/pubmed/27756975